In this webinar, Dr. Keith Wharton reviews a set of published studies using single cell analysis of lung tissues that have provided ground breaking insight into lung development and disease.

Antigen Background Thyroid Transcription Factor-1 (TTF-1) is a member of the homeodomain transcription factor family and plays a role in regulating genes expressed within the thyroid, lung and brain. These include thyroglobulin, thyroid peroxidase, Clara cell secretory protein and surfactant proteins. Human TTF-1 (38 kD) is a single polypeptide of 371 amino acids sharing 98% homology with the equivalent rat and mouse proteins. TTF-1 functions by ...

Antigen Background Cytokeratins are intermediate filament proteins present in epithelial cells. They are expressed in a tissue-specific manner in normal organs and the tumors that arise from them. Cytokeratin 7 belongs to the neutral basic type B subfamily of cytokeratins. Its distribution is confined to glandular and transitional epithelia. Cytokeratin 7 is reported to be expressed in abundance in cultured bronchial and mesothelial cells but onl...

Deletions of chromosome 13q14 have been reported not only in CLL but in a variety of human tumors, including other types of lymphoid and myeloid tumors, as well as prostate, head and neck, and non-small cell lung cancers. The deletion of 13q may be limited to a single locus (13q14), or accompanied with the loss of a larger interstitial region of the long arm of chromosome 13. A minimal critical region of 400 kb has been described containing the D...

Translocations of the ALK (anaplastic lymphoma kinase) gene at 2p23 have originally been associated with anaplastic lymphomas, B-cell lymphomas, neuroblastomas and myofibroblastic tumors. At least 21 translocation partners have been described, however 80% of the translocations involves the NPM1 gene (5q35). ALK rearrangements have been described in non-small cell lung cancer (NSCLC) cases. Multiple tyrosine kinsae inhibitors (TKI's) specific for ...

Incorporation and Automation of RNAscope Technology into your COVID-19 Viral Pathogenesis Research. Research Use Only, Not for Clinical Diagnostic Procedure For Research Use Only. Not For Diagnostic Use. Incorporation of the highly sensitive and specific RNAscope technology into your COVID-19 Viral Pathogenesis Research Jyoti Sheldon Applications Research Use Only, Not for Clinical Diagnostic Procedure Agenda RNAscope technology overview COVID-19 Offerings COVID-19 Publications Research Use Only, Not for Clinical Diagnostic Procedure RNAscope®In Situ Hybridization (ISH) Technology A hybridization-based signal amplification system with a unique probe design - Simultaneous signal amplification and background suppression Amplification Target-specific binding A specific and sensit...

Slide 1 Welcome Slide 2 Slide 3 Discuss Pre-Analytics and the impact of improper fixation and artifacts on tissue processing Discuss Fixation and the impact of incomplete fixation on tissue processing Describe the impact of improper Prosection Determine satisfactory Processing of samples Explain why routine Maintenance is a critical success factor to proper tissue processing Slide 4 This slide has two examples of what the ideal sections in a perfect world look like under the scope. The skin section on the left is clean looking with the Eosin staining the components of the dermis with different shades. The colon section on the right is crisp with well-defined nuclei and cilia. There is no background staining or muddiness to the stain. Slide 5 One artifact seen the lab that is n...

It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects. Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...

Slide 1 Hello, hello; thank you so much for that introduction. Let's get started. Oh, I'm sorry, I just need to hit this next button here. So my name is Mark Lawson. Thank you for joining us in this webinar. I'm here to present BOND RX tips, tricks, and optimization. It's going to be a user guide from the BOND RX and chromogenic multiplexing in the research application. Slide 2 So, my name is Mark Lawson. I'm an application specialist on the Life Sciences team at Leica Biosystems I provide technical support for the Life Sciences portfolio, including but not limited to the BOND RX, the BOND RXm, and a wide array of reagents. So I've worked in the histology field for about 15 years and in both clinical and research spaces. I started off as a histotechnologist and worked my way up...

The Power of Digital Pathology in Research 1. Leica Biosystems Proprietary Information. For Research Use Only. Not For Use in Diagnostic The Power of Digital Pathology In Research. Caitríona Lyons PhD. 2. Introduction • Caitríona Lyons PhD • Based in Dublin, Ireland • Current Role: • Product Manager Image Analysis, Leica Biosystems • Previous Roles: • Product Owner Image Analysis, Leica Biosystems • Image Analysis Specialist, Leica Biosystems • Education • BSc (Hons) Biomedical Science • PhD Medicine and Health • Postdoc Immunology 3. Agenda • History of Pathology • What is Digital Pathology • Power of Digital Pathology • Leica Biosystems Role in Digital Pathology • The Future of Digital Pathology • Final Thoughts 3 SCAN MANAGE ANALYZE 4. History of Digital Pathology • Patholog...